1. Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers
- Author
-
Raphaela S. Milona, Stylianos Chatzipanagiotou, Alexandra Tsirogianni, Anastasia Bletsa, Kostas Patas, Nikolaos Papamichalopoulos, Emmanouil Angelakis, Meropi Gkika, Ioannis Manolis, Anastasios Ioannidis, Niki Vassilaki, Dimitrios Theodoridis, Antonios N. Gargalionis, Elisavet Kontou, Hellenic Pasteur Institute, National and Kapodistrian University of Athens (NKUA), University of Athens Medical School [Athens], University of Peloponnese, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Eginition Hospital, Institut Pasteur Hellénique, Réseau International des Instituts Pasteur (RIIP), and Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,QH301-705.5 ,Microbiology ,Gastroenterology ,BNT162b2 mRNA ,03 medical and health sciences ,SARS-CoV-2 IgG ,0302 clinical medicine ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Interquartile range ,Virology ,Internal medicine ,Medicine ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,ADVIA Centaur ,030212 general & internal medicine ,Biology (General) ,Volunteer ,030304 developmental biology ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,0303 health sciences ,business.industry ,healthcare workers ,Communication ,Antibody titer ,COVID-19 ,Venous blood ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,3. Good health ,Vaccination ,Titer ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Analysis of variance ,business - Abstract
Anti-SARS-CoV-2 spike RBD (receptor-binding domain) IgG antibody levels were monitored in 1643 volunteer healthcare workers of Eginition, Evangelismos, and Konstantopoulio General Hospitals (Athens, Greece), who underwent vaccination with two doses of COVID-19 BNT162b2 mRNA vaccine (Pfizer) and had no history of SARS-CoV-2 infection. Venous blood was collected 20–30 days after the second vaccine dose and anti-RBD IgG levels were determined using CMIA SARS-CoV-2 IgG II Quant (Abbott) on ARCHITECT i System or ADVIA Centaur SARS-CoV-2 IgG (Siemens) on Centaur XP platform. From the total population of 1643 vaccinees (533 M/1110 F; median age = 49; interquartile range-IQR = 40–56), 1636 (99.6%) had anti-SARS-CoV-2 IgG titers above the positivity threshold of the assay used. One-Way ANOVA Kruskal-Wallis H test showed a statistically significant difference in the median of antibody titers between the different age groups (p < 0.0001). Consistently, Spearman’s correlation coefficient (r) for IgGs and age as continuous variables was −0.2380 (p = 1.98 × 10−17). Moreover, antibody titers were slightly higher by 1.2-mean fold (p = 3 × 10−6) in the total female population of the three hospitals (median = 1594; IQR = 875–2584) as compared to males (median = 1292; IQR = 671.9–2188). The present study supports that BNT162b2 vaccine is particularly effective in producing high anti-SARS-CoV-2 IgG levels in healthy individuals, and this humoral response is age- and gender-dependent.
- Published
- 2021